IP Library › Granted Patent US 9,840,491

Granted Patent B2

US 9,840,491 · App. 15/015,571 · Granted Dec 12, 2017

Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Inventors: Stephanos Ioannidis (Natick, MA); Adam Charles Talbot (Guilford, CT); Bruce Follows (Littleton, MA); Alexandre Joseph Buckmelter (Acton, MA); Minghua Wang (Acton, MA); Ann-Marie Campbell (Monroe, CT); David R. Lancia, Jr. (Boston, MA)

Assignee: FORMA Therapeutics, Inc.

C07D401/06 C07D239/88 C07D471/04 C07D487/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,840,491
App. No.: 15/015,571
Granted: Dec 12, 2017
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R 1 , R 2 , R 3 , R 4 , R 4′ , X 1 , Y 1 , Y 2 , Y 3 , Y 4 , n, and m are described herein.

Claims (217)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt, stereoisomer, and tautomer thereof,

wherein:

X 1 is C, S, or S(O);

Y 1 is N or CH;

Y 2 is N or CR 5 ;

Y 3 is N or CR 6 ;

Y 4 is N or CR 7 ;

R 1 is H, —OH, —SH, —NH 2 , or F;

R 2 is (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, or —NR 10 R 11 , wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 8 ;

each R 3 is independently at each occurrence selected from D, (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 3 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 20 ; or

two R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a 3- to 7-membered spiroheterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ;

R 4 and R 4′ are independently H, D, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, or CN;

R 5 is H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) haloalkyl, halogen, NO 2 , or CN, wherein the alkyl, alkenyl, and alkynyl are optionally substituted with one to three R 12 ;

R 6 is H, D, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, NO 2 , —NH 2 , —NHC(O)(C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 13 ;

R 7 is H, (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 6 -C 14 ) aryl, —O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —N((C 1 -C 6 ) alkyl)-(C 6 -C 14 ) aryl, —NH—(C 6 -C 14 ) aryl, —N((C 1 -C 6 ) alkyl)-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, or —NH-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 14 ;

wherein R 5 , R 6 , and R 7 are not all simultaneously H;

each R 8 is independently D, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, —(C 1 -C 3 )-alkylene-O—(C 1 -C 6 ) alkyl, —(C 0 -C 4 )-alkylene-(C 6 -C 14 ) aryl, —(C 0 -C 4 )-alkylene-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 3 -C 10 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —(C 0 -C 4 )-alkylene-O—(C 6 -C 14 ) aryl, —(C 0 -C 4 )-alkylene-O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 3 -C 8 ) cycloalkyl, —S-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —C(O)R 21 , —CO(O)R 21 , —C(O)NR 21 R 22 , —S(O) q R 21 , —S(O) q NR 21 R 22 , —NR 21 S(O) q R 22 , —(C 0 -C 3 )-alkylene-NR 21 R 22 , —NR 21 C(O)R 22 , —NR 21 C(O)C(O)R 22 , —NR 21 C(O)NR 21 R 22 , —P(O)((C 1 -C 6 ) alkyl) 2 , —P(O)((C 6 -C 14 ) aryl) 2 , —SiMe 3 , —SF 5 , or —OR 21 , wherein the alkyl, alkylene, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 9 ; or

two R 8 together when on adjacent atoms form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ;

each R 9 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, (C 3 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —(C 0 -C 3 )-alkylene-(C 6 -C 14 ) aryl, —(C 0 -C 3 )-alkylene-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —NH 2 , —OH, —C(O)R 23 , —C(O)NR 23 R 24 , —NR 23 C(O)R 24 , —NR 23 R 24 , —S(O) q R 23 , —S(O) q NR 23 R 24 , —NR 23 S(O) q R 24 , oxo, —P(O)((C 1 -C 6 ) alkyl) 2 , —P(O)((C 6 -C 14 ) aryl) 2 , —SiMe 3 , —SF 5 , —O—(C 6 -C 14 ) aryl, CN, or —O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 19 ;

R 10 and R 11 are independently H, (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 17 ; or

R 10 and R 11 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S, optionally substituted with one to three R 17 ;

each R 12 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, —NH 2 , (C 1 -C 6 ) alkylamino, or di(C 1 -C 6 ) alkylamino;

each R 13 is independently D, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, —OH, —NH 2 , —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 3 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 6 -C 14 ) aryl, —O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —O-3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 3 -C 8 ) cycloalkyl, —C(O)O(C 1 -C 6 ) alkyl, —C(O)NR 26 R 27 , —S(O) q NR 26 R 27 , —NR 26 R 27 , —NR 26 C(O)NR 26 R 27 , —NR 26 C(O)OR 27 , —NR 26 S(O) q R 27 , —NR 26 C(O)R 27 , halogen, —P(O)((C 1 -C 6 ) alkyl) 2 , —P(O)((C 6 -C 14 ) aryl) 2 , —SiMe 3 , or —SF 5 , wherein in the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 15 ;

each R 14 is independently D, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, —OH, —NH 2 , —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 3 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 6 -C 14 ) aryl, —O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —O-3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 3 -C 8 ) cycloalkyl, —C(O)O(C 1 -C 6 ) alkyl, —C(O)NR 26 R 27 , —S(O) q NR 26 R 27 , —NR 26 R 27 , —NR 26 C(O)NR 26 R 27 , —NR 26 C(O)OR 27 , —NR 26 S(O) q R 27 , —NR 26 C(O)R 27 , halogen, —P(O)((C 1 -C 6 ) alkyl) 2 , —P(O)((C 6 -C 14 ) aryl) 2 , —SiMe 3 , or —SF 5 , wherein in the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 16 ;

each R 15 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, —NH 2 , (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, —OH, or CN;

each R 16 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, —NH 2 , (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 3 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 6 -C 14 ) aryl, —O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —O-3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 3 -C 8 ) cycloalkyl, —OH, or CN, wherein in the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 28 ;

each R 17 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, (C 1 -C 6 ) hydroxyalkyl, —OH, CN, —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, —NH 2 , (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein in the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 18 ;

each R 18 is independently (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, —NH 2 , (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, —OH, or CN;

each R 19 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —NR 26 C(O)R 27 , —NR 26 S(O) q R 27 , —C(O)R 26 , —C(O)NR 26 R 27 , —NR 26 R 27 , —S(O) q R 26 , —S(O) q NR 26 R 27 , —P(O)((C 1 -C 6 ) alkyl) 2 , —P(O)((C 6 -C 14 ) aryl) 2 , —SiMe 3 , —SF 5 , —OH, or CN;

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 21 and R 22 is independently H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one to three R 25 ;

each R 23 and R 24 is independently H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one to three R 25 ;

each R 25 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

each R 26 and R 27 is independently at each occurrence H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl are optionally substituted with one to three substituents independently selected from (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, —NH 2 , (C 1 -C 6 ) alkylamino, or di(C 1 -C 6 ) alkylamino;

each R 28 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —C(O)(C 1 -C 6 ) alkyl, —S(O) q (C 1 -C 6 ) alkyl, —NH 2 , (C 1 -C 6 ) alkylamino, di(C 1 -C 6 ) alkylamino, —OH, or CN;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3;

q is independently at each occurrence 0, 1, or 2; and

provided that when R 2 is optionally substituted alkyl, R 5 is H, and R 7 is H, then R 6 is not chloro.

2. The compound of claim 1 , wherein X 1 is C.

3. The compound of claim 1 , wherein R 1 is —OH.

4. The compound of claim 1 , wherein R 2 is (C 1 -C 6 ) alkyl or (C 6 -C 14 ) aryl, wherein the alkyl and aryl are optionally substituted with one to three R 8 .

5. The compound of claim 1 , wherein R 4 is H.

6. The compound of claim 1 , wherein R 4′ is H.

7. The compound of claim 1 , wherein is Y 2 is N or CR 5 and R 5 is H.

8. The compound of claim 1 , wherein Y 3 is N or CR 6 and R 6 is H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, —NH 2 , —NHC(O)(C 1 -C 6 ) alkyl, or (C 6 -C 14 ) aryl, wherein the alkyl, and aryl are optionally substituted with one to three R 13 .

9. The compound of claim 1 , wherein Y 4 is N or CR 7 and R 7 is H, (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, or —O—(C 6 -C 14 ) aryl, wherein the alkyl and aryl are optionally substituted with one to three R 14 .

10. The compound of claim 1 , wherein n is 1.

11. The compound of claim 1 , having Formula (Ia), Formula (Ib), or Formula (Ic):

or a pharmaceutically acceptable salt, stereoisomer, and tautomer thereof,

wherein:

X 1 is C, S, or S(O);

two R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a 3- to 7-membered spiroheterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ;

wherein R 5 , R 6 , and R 7 are not all simultaneously H;

two R 8 together when on adjacent atoms form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ;

R 10 and R 11 together with the nitrogen to which they are attached form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 17 ,

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 25 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3;

q is independently at each occurrence 0, 1, or 2; and

provided that when R 2 is optionally substituted alkyl, R 5 is H, and R 7 is H, R 6 is not chloro.

12. The compound of claim 1 , having Formula (Id) or Formula (Ie):

or a pharmaceutically acceptable salt, stereoisomer, and tautomer thereof,

wherein:

two R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a 3- to 7-membered spiroheterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ;

R 6 is D, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, NO 2 , —NH 2 , —NHC(O)(C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, or 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 13 ;

R 7 is (C 1 -C 6 ) alkyl, (C 6 -C 14 ) aryl, 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 5 -C 8 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 6 -C 14 ) aryl, —O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —N((C 1 -C 6 ) alkyl)-(C 6 -C 14 ) aryl, —NH—(C 6 -C 14 ) aryl, —N((C 1 -C 6 ) alkyl)-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, or —NH-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, wherein the alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 14 ;

two R 8 together when on adjacent atoms form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ;

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 25 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3;

q is independently at each occurrence 0, 1, or 2; and

provided that when R 2 is optionally substituted alkyl, R 6 is not chloro.

13. The compound of claim 1 , having Formula (If) or Formula (Ig):

or a pharmaceutically acceptable salt, stereoisomer, and tautomer thereof,

wherein:

X 1 is C, S, or S(O);

two R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a 3- to 7-membered spiroheterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ;

each R 7 is independently D, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, CN, —(C 1 -C 3 )-alkylene-O—(C 1 -C 6 ) alkyl, —(C 0 -C 4 )-alkylene-(C 6 -C 14 ) aryl, —(C 0 -C 4 )-alkylene-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, (C 3 -C 10 ) cycloalkyl, 3- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S, —(C 0 -C 4 )-alkylene-O—(C 6 -C 14 ) aryl, —(C 0 -C 4 )-alkylene-O-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —O—(C 3 -C 8 ) cycloalkyl, —S-5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from O, N, and S, —C(O)R 21 , —CO(O)R 21 , —C(O)NR 21 R 22 , —S(O) q R 21 , —S(O) q NR 21 R 22 , —NR 21 S(O) q R 22 , —(C 0 -C 3 )-alkylene-NR 21 R 22 , —NR 21 C(O)R 22 , —NR 21 C(O)C(O)R 22 , —NR 21 C(O)NR 21 R 22 , —P(O)((C 1 -C 6 ) alkyl) 2 , —P(O)((C 6 -C 14 ) aryl) 2 , —SiMe 3 , —SF 5 , or —OR 21 , wherein the alkyl, alkylene, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl are optionally substituted with one to three R 9 ; or

two R 8 together when on adjacent atoms form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ;

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 25 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3; and

q is independently at each occurrence 0, 1, or 2.

14. The compound of claim 1 , having Formula (Ih):

or a pharmaceutically acceptable salt, stereoisomer, and tautomer thereof,

wherein:

X 1 is C, S, or S(O);

two R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a 3- to 7-membered spiroheterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ;

two R 8 together when on adjacent atoms form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ;

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 25 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3; and

q is independently at each occurrence 0, 1, or 2.

15. The compound of claim 1 , having Formula (Ii):

or a pharmaceutically acceptable salt, stereoisomer, and tautomer thereof,

wherein:

X 1 is C, S, or S(O);

two R 3 together when on adjacent carbons form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl optionally substituted with one to three R 20 ; or two R 3 together when attached to the same carbon atom form a 3- to 7-membered spiroheterocycloalkyl comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 20 ; or two R 3 together when on adjacent carbons form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 20 ;

two R 8 together when on adjacent atoms form a (C 3 -C 8 ) cycloalkyl optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 3- to 7-membered heterocycloalkyl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a (C 6 -C 14 ) aryl ring optionally substituted with one to three R 9 ; or two R 8 together when on adjacent atoms form a 5- or 6-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from O, N, and S optionally substituted with one to three R 9 ;

each R 20 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, —NH 2 , or CN;

each R 25 is independently at each occurrence (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, —OH, or CN;

m is 0, 1, 2, 3, or 4;

n is 0, 1, 2, or 3; and

q is independently at each occurrence 0, 1, or 2.

16. A compound selected from:

3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-7-methoxyquinazolin-4(3H)-one;

3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-8-methylquinazolin-4(3H)-one;

7-amino-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)quinazolin-4(3H)-one;

N-(3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydroquinazolin-7-yl)acetamide;

(R)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-7-methoxyquinazolin-4(3H)-one;

(R)-3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)-8-methylquinazolin-4(3H)-one;

3-((1-(1-benzylindoline-5-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-methylquinazolin-4(3H)-one;

3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-7-phenylquinazolin-4(3H)-one;

3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-8-phenylquinazolin-4(3H)-one;

3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-8-(4-fluorophenoxy)quinazolin-4(3H)-one;

3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrido[2,3-d]pyrimidin-4(3H)-one;

3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one; or

3-((4-hydroxy-1-(3-phenylbutanoyl)piperidin-4-yl)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one.

17. A pharmaceutical composition comprising, a compound of claim 1 , and a pharmaceutically acceptable carrier.

Assignments (6)

RELEASE OF SECURITY INTEREST Recorded Oct 17, 2023

From: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT

To: VALO HEALTH, INC.; VALO HEALTH, LLC

Reel/Frame 065255/0660 →

SECURITY INTEREST Recorded Jul 6, 2023

From: VALO HEALTH, LLC; VALO HEALTH, INC.

To: FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT

Reel/Frame 064207/0957 →

MERGER Recorded Sep 8, 2021

From: VALO EARLY DISCOVERY, INC.

To: VALO HEALTH, INC.

Reel/Frame 057438/0025 →

CHANGE OF NAME Recorded Sep 16, 2020

From: INTEGRAL EARLY DISCOVERY, INC.

To: VALO EARLY DISCOVERY, INC.

Reel/Frame 053787/0138 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2020

From: FORMA THERAPEUTICS, INC.

To: INTEGRAL EARLY DISCOVERY, INC.

Reel/Frame 053402/0298 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 29, 2016

From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH; WANG, MINGHUA; CAMPBELL, ANN-MARIE; LANCIA, DAVID, JR.

To: FORMA THERAPEUTICS, INC.

Reel/Frame 037852/0066 →

Continuity (2)

Provisional Application 62112487 · Feb 5, 2015

Related Publication 20160229833A1 · Aug 11, 2016